Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial

By sjmartinez • November 29, 2022

Hanscom BS, Donnell DJ, Fleming TR, Hughes JP, McCauley M, Grinsztejn B, Landovitz RJ, Emerson SS. Evaluating group-sequential non-inferiority clinical trials following interim stopping: The HIV Prevention Trials Network 083 trial. Clin Trials. 2022 Dec;19(6):605-612. doi: 10.1177/17407745221118371. Epub 2022 Sep 2. PMID: 36053045; PMCID: PMC9691580.

Tags: early stopping, Group-sequential trials, HPTN 083, Infectious Diseases, non-inferiority, Publications

Safety, tolerability, pharmacokinetics, and neutralisation activities of the anti-HIV-1 monoclonal antibody PGT121.414.LS administered alone and in combination with VRC07-523LS in adults without HIV in the USA (HVTN 136/HPTN 092): a first-in-human, open-label, randomised controlled phase 1 trial

Edupuganti S, Hurt CB, Stephenson KE, Huang Y, Paez CA, Yu C, Yen C, Hanscom B, He Z, Miner MD, Gamble T, Heptinstall J, Seaton[...]

Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024

Caldera JR, Shaw B, Uslan DZ, Yang S. Cluster of Extensively Drug-Resistant Shigella sonnei Carrying blaCTX-M-15 in Los Angeles, California, 2023-2024. Am J Infect Control. 2024[...]

Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status

Lo Re V 3rd, Newcomb CW, Carbonari DM, Mezochow AK, Hennessy S, Rentsch CT, Park LS, Tate JP, Bräu N, Bhattacharya D, Lim JK, Mezzacappa[...]